Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 11/2005

01.11.2005 | Original Article

Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain

verfasst von: Guo Xiaoling, Liu Ying, Liu Jing, Li Huifang, Zhu Xia, Fan Qingqing, Zhu Ping

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

The variable domain of immunoglobulin heavy chain (Ig HV) is well-characterized tumor associated antigen expressed in B-cell malignancies, which may function as a T-cell target. However, T-cell epitopes derived from shared framework regions (FRs) of each IgHV subfamily capable of inducing cytotoxic T lymphocytes (CTLs) against the B-cell malignancy, have not been identified. Using the specific PCR primers of seven IgHV gene subfamilies, we amplified the IgHV gene rearrangement for 108 cases of B-cell acute lymphoblastic leukemia (B-ALL) patients. The IgHV gene rearrangement fragments of B-ALL patients were directly sequenced then classified into seven different subfamilies. The T-cell epitopes encoded by the IgHV gene in the B-ALL patients were predicted by SYFPEITHI and BIMAS programs and compared with those from 56 representative germline IgHV sequences in the genebank. For the HLA-A*0201 locus, we found 1 or 2 top score shared epitopes from each subfamily and got 12 epitopes altogether. Results showed that ten of them were in the FRs. Using an antigen-specific T-cell expansion system, we generated the peptide-special CTLs in vitro, which were capable of killing B lymphoma cell lines that belonged to the same IgHV subfamily in a peptide-specific and HLA-restricted manner. Furthermore, we proved that the cytotoxicity of CTLs was IgHV subfamily-specific. These data indicate possible immunotherapy approaches for B-cell malignances patients based on IgHV gene subfamilies.
Literatur
1.
Zurück zum Zitat Janeway CA Jr, Sakato N, Eisen HN (1975) Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci USA 72(6):2357–2360PubMed Janeway CA Jr, Sakato N, Eisen HN (1975) Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci USA 72(6):2357–2360PubMed
2.
Zurück zum Zitat Bogen B, Malissen B, Haas W (1986) Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16(11):1373–1378PubMed Bogen B, Malissen B, Haas W (1986) Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16(11):1373–1378PubMed
3.
Zurück zum Zitat Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R (1987) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 15 139(8):2825–2833 Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R (1987) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 15 139(8):2825–2833
4.
Zurück zum Zitat Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell malignancies with monoclonal anti-idiotype antibody. N Engl J Med 4 306(9):517–522 Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell malignancies with monoclonal anti-idiotype antibody. N Engl J Med 4 306(9):517–522
5.
Zurück zum Zitat Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R (1990) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145(3):1029–1036PubMed Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R (1990) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145(3):1029–1036PubMed
6.
Zurück zum Zitat Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R (1992) Monoclonal anti-idiotype antibody therapy of B-cell malignancies: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80(6):1502–1510PubMed Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R (1992) Monoclonal anti-idiotype antibody therapy of B-cell malignancies: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80(6):1502–1510PubMed
7.
Zurück zum Zitat Chen TT, Tao MH, Levy R (1994) Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153(10):4775–4787PubMed Chen TT, Tao MH, Levy R (1994) Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153(10):4775–4787PubMed
8.
Zurück zum Zitat Barrios Y, Cabrera R, Yanez R, Briz M, Plaza A, Fores R (2002) Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87(4):400–407PubMed Barrios Y, Cabrera R, Yanez R, Briz M, Plaza A, Fores R (2002) Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87(4):400–407PubMed
9.
Zurück zum Zitat Ruffini PA, Neelapu SS, Kwak LW, Biragyn A (2002) Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87(9):989–1001PubMed Ruffini PA, Neelapu SS, Kwak LW, Biragyn A (2002) Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87(9):989–1001PubMed
10.
Zurück zum Zitat Wen YJ, Lim SH. (1997) T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin’s lymphoma. Eur J Immunol 27(4):1043–1047PubMed Wen YJ, Lim SH. (1997) T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin’s lymphoma. Eur J Immunol 27(4):1043–1047PubMed
11.
Zurück zum Zitat Fagerberg J, Yi Q, Gigliotti D, Harmenberg U, Ruden U, Persson B, Osterborg A, Mellstedt H (1999) T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer 80(5):671–680CrossRefPubMed Fagerberg J, Yi Q, Gigliotti D, Harmenberg U, Ruden U, Persson B, Osterborg A, Mellstedt H (1999) T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer 80(5):671–680CrossRefPubMed
12.
Zurück zum Zitat Wen YJ, Lim SH (1999) Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma. Scand J Immunol 50(3):296–301CrossRefPubMed Wen YJ, Lim SH (1999) Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma. Scand J Immunol 50(3):296–301CrossRefPubMed
13.
Zurück zum Zitat Rezvany MR, Jeddi-Tehrani M, Rabbani H, Ruden U, Hammarstrom L, Osterborg A, Wigzell H, Mellstedt H (2000) Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 111(1):230–238CrossRefPubMed Rezvany MR, Jeddi-Tehrani M, Rabbani H, Ruden U, Hammarstrom L, Osterborg A, Wigzell H, Mellstedt H (2000) Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 111(1):230–238CrossRefPubMed
14.
Zurück zum Zitat Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H (2003) T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 101(12):4930–4936CrossRefPubMed Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H (2003) T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 101(12):4930–4936CrossRefPubMed
15.
Zurück zum Zitat Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6(6):667–672CrossRefPubMed Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6(6):667–672CrossRefPubMed
16.
Zurück zum Zitat Lou Q, Kelleher RJ Jr, Sette A, Loyall J, Southwood S, Bankert RB, Bernstein SH (2004) Germ line tumor-associated immunoglobulin IgHV region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood 104(3):752–759CrossRefPubMed Lou Q, Kelleher RJ Jr, Sette A, Loyall J, Southwood S, Bankert RB, Bernstein SH (2004) Germ line tumor-associated immunoglobulin IgHV region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood 104(3):752–759CrossRefPubMed
17.
Zurück zum Zitat Scaviner D, Barbie V, Ruiz M, Lefranc MP (1999) Protein displays of the human immunoglobulin heavy, kappa and lambda variable and joining regions. Exp Clin Immunogenet 16(4):234–240CrossRefPubMed Scaviner D, Barbie V, Ruiz M, Lefranc MP (1999) Protein displays of the human immunoglobulin heavy, kappa and lambda variable and joining regions. Exp Clin Immunogenet 16(4):234–240CrossRefPubMed
18.
Zurück zum Zitat Lin NJ, Zhu P, Zhang YP, Shi YJ, Zhang X, Bu DF, Dong YJ (2002) The experimental study on the idiotypic nucleic Acid vaccine constructed from the genomic DNA to lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10(2):126–130PubMed Lin NJ, Zhu P, Zhang YP, Shi YJ, Zhang X, Bu DF, Dong YJ (2002) The experimental study on the idiotypic nucleic Acid vaccine constructed from the genomic DNA to lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10(2):126–130PubMed
19.
Zurück zum Zitat Lin N, Zhu P, Zhang X, Dong Y, Ren Y, Wang Y, Li W (2002) Specific humoral immune response against B-cell lymphoma elicited by mixed immunoglobulin fragments. Zhonghua Yi Xue Za Zhi 82(11):766–770PubMed Lin N, Zhu P, Zhang X, Dong Y, Ren Y, Wang Y, Li W (2002) Specific humoral immune response against B-cell lymphoma elicited by mixed immunoglobulin fragments. Zhonghua Yi Xue Za Zhi 82(11):766–770PubMed
20.
Zurück zum Zitat Liu H, Zhu P, Lin NJ, Zhang Y, Bu DF, Wang YJ, Wang YQ, Yang Y (2004) Development of IgHV family specific nucleic acid vaccine against lymphoma by construction of fusion gene of immunoglobulin heavy chain variable region and cytokine. Zhonghua Yi Xue Za Zhi 84(1):48–53PubMed Liu H, Zhu P, Lin NJ, Zhang Y, Bu DF, Wang YJ, Wang YQ, Yang Y (2004) Development of IgHV family specific nucleic acid vaccine against lymphoma by construction of fusion gene of immunoglobulin heavy chain variable region and cytokine. Zhonghua Yi Xue Za Zhi 84(1):48–53PubMed
21.
Zurück zum Zitat Zhang Y, Zhu P, Shi Y, Liu J, Pu D, Cao X, Zhu Q, Wang Y, Ma M, Yu J (2002) Experimental study on TCRbeta idiotypic antigenic determinants DNA vaccine to induce anti-lymphoma antibodies. Zhonghua Xue Ye Xue Za Zhi 23(2):68–72PubMed Zhang Y, Zhu P, Shi Y, Liu J, Pu D, Cao X, Zhu Q, Wang Y, Ma M, Yu J (2002) Experimental study on TCRbeta idiotypic antigenic determinants DNA vaccine to induce anti-lymphoma antibodies. Zhonghua Xue Ye Xue Za Zhi 23(2):68–72PubMed
22.
Zurück zum Zitat Liu Y, Zhu P, Hu YM (2004) Characteristics of immunoglobulin heavy chain variable region genes in childhood B-cell acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 25(1):8–12PubMed Liu Y, Zhu P, Hu YM (2004) Characteristics of immunoglobulin heavy chain variable region genes in childhood B-cell acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 25(1):8–12PubMed
23.
Zurück zum Zitat Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673–679CrossRefPubMed Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673–679CrossRefPubMed
24.
Zurück zum Zitat Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60(16):4499–4506PubMed Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60(16):4499–4506PubMed
25.
Zurück zum Zitat Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Seran C (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98(10):2887–2893CrossRefPubMed Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Seran C (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98(10):2887–2893CrossRefPubMed
26.
Zurück zum Zitat Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA (2003) Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102(10):3530–3540CrossRefPubMed Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA (2003) Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102(10):3530–3540CrossRefPubMed
27.
Zurück zum Zitat Yang YH, Li HF, Zhu P (2003) The T-lymphocyte clonal proliferation in a patient with chronic eosinophilic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11(4):405–408PubMed Yang YH, Li HF, Zhu P (2003) The T-lymphocyte clonal proliferation in a patient with chronic eosinophilic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11(4):405–408PubMed
28.
Zurück zum Zitat Weidmann E, Brieger J, Jahn B, Hoelzer D, Bergmann L, Mitrou PS (1995) Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol 70(3):153–158CrossRefPubMed Weidmann E, Brieger J, Jahn B, Hoelzer D, Bergmann L, Mitrou PS (1995) Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol 70(3):153–158CrossRefPubMed
29.
Zurück zum Zitat Harig S, Witzens M, Krackhardt AM, Trojan A, Barrett P, Broderick R, Zauls AJ, Gribben JG (2001) Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 98(10):2999–3005CrossRefPubMed Harig S, Witzens M, Krackhardt AM, Trojan A, Barrett P, Broderick R, Zauls AJ, Gribben JG (2001) Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 98(10):2999–3005CrossRefPubMed
Metadaten
Titel
Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain
verfasst von
Guo Xiaoling
Liu Ying
Liu Jing
Li Huifang
Zhu Xia
Fan Qingqing
Zhu Ping
Publikationsdatum
01.11.2005
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 11/2005
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0696-z

Weitere Artikel der Ausgabe 11/2005

Cancer Immunology, Immunotherapy 11/2005 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.